Postprandial Metabolism After Bariatric Surgery in Type 2 Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-08-31

Study Completion Date

2019-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bariatric surgery procedures have now been firmly demonstrated to lead to significant improvement and even, in many cases, complete reversal of abnormal glucose homeostasis in type 2 diabetes (T2D). Various surgery procedures are can be performed to induce weight loss. The most striking anti-diabetic effects are observed with biliopancreatic diversion with duodenal switch (BPD-DS), followed by Roux-in-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). The first two procedures induce both a restriction of energy intake and a low absorption of dietary fatty acids while the latter exclusively targets energy intake restriction. The investigator and others have shown that improvement of T2D occurs within days after BPD-DS or RYGB in the vast majority of patients, prior to any significant weight loss. This very rapid metabolic recovery is explained by a normalization of β-cell function after meal challenges and ameliorated hepatic insulin sensitivity. The investigator and others have shown that these acute anti-diabetic effects are mostly recapitulated by matched caloric restriction, independent of changes in gastrointestinal hormones, showing the importance of gastrointestinal-derived energy fluxes for acute diabetes control. Muscle insulin sensitivity, on the other hand, improves more slowly in association with weight loss, demonstrating the heterogeneous metabolic response of the various organs to BPD-DS. Some preliminary studies also demonstrate a rapid reduction of NEFA levels and production rate upon i.v. administration of lipids during euglycemic hyperinsulinemic clamps. This very rapid improvement in NEFA tolerance strongly suggests that adipose tissue storage of circulating fatty acids also improves very rapidly, prior to any significant weight loss, after BPD-DS. It may also suggest an acceleration of oxidative fatty acid metabolism in organs such as the liver, the heart and/or skeletal muscles. Studies of the rapid metabolic changes after bariatric surgery conducted thus far rapidly improved the understanding of the fundamental pathogenic defects of T2D. However, much remains to be understood about the acute changes in gastrointestinal-derived metabolic fluxes, organ-specific metabolic responses to bariatric surgery and their relationship with the reversal of T2D. Using in vivo methodological approaches, the investigator proposes to investigate the early organ-specific changes in dietary fatty acid metabolism in response to BPD-DS vs. SG and their relation to improved systemic changes in glucose homeostasis, insulin sensitivity and β-cell function in patients with T2D.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Laparoscopic Bariatric Surgery to Treat Type 2 Diabetes in Obese Patients

NCT00428571

Type 2 Diabetes

TERMINATED NA

GLP1-imaging Before and After Bariatric Surgery

NCT03182231

Diabetes Mellitus, Type 2 Bariatric Surgery Candidate

UNKNOWN PHASE1/PHASE2

Effect of Bariatric Surgery on Brain Insulin Sensitivity

NCT03705923

Obesity

TERMINATED NA

An Analysis of Lipid and Glucose Metabolism Following Bariatric Surgery

NCT02067585

Morbid Obesity

COMPLETED NA

Effects of Caloric Restriction Alone Versus Postoperative Caloric Restriction Following Bariatric Surgery on Glucose Metabolism in Patients With Diabetes Mellitus

NCT01083108

Obesity Bariatric Surgery Morbid Obesity +2 more

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Participants will undergo a metabolic study before and 8 to 12 days after bariatric surgery after a 12-hour fast and a three-day food and physical activity diary with accelerometry. The patients recover very rapidly from the surgery and will be able to participate to the proposed investigations the week after their hospitalization on an outpatient basis on the earliest week day between 8 and 12 days after the surgery procedure. The metabolic study is a 6-hour meal test using Positron Emitting Tomography (PET).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Obese

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Before DBP-DS surgery

Group Type OTHER

liquid meal

Intervention Type OTHER

will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose

PET/scan

Intervention Type RADIATION

a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA

[7,7,8,8-2H]-palmitate

Intervention Type OTHER

i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.

indirect calorimetry

Intervention Type DEVICE

will be performed every hour throughout the protocol along with exhaled breath collection

After DBP-DS surgery

It is a bariatric surgery. BPD consists in the exclusion of the duodenum from the alimentary tract with re-anastomosis of the blind loop 100 to 150 cm proximal to the ileo-coecal valve. This leads to bypass of the biliopancreatic secretions towards the distal small intestine, resulting in fat malabsorption. BPD also entails a distal gastrectomy to avoid the occurrence of peptic ulceration of the gastrointestinal anastomosis.

Group Type EXPERIMENTAL

biliopancreatic diversion with duodenal switch

Intervention Type PROCEDURE

liquid meal

Intervention Type OTHER

will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose

PET/scan

Intervention Type RADIATION

a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA

[7,7,8,8-2H]-palmitate

Intervention Type OTHER

i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.

indirect calorimetry

Intervention Type DEVICE

will be performed every hour throughout the protocol along with exhaled breath collection

Before SG surgery

Group Type OTHER

liquid meal

Intervention Type OTHER

will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose

PET/scan

Intervention Type RADIATION

a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA

[7,7,8,8-2H]-palmitate

Intervention Type OTHER

i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.

indirect calorimetry

Intervention Type DEVICE

will be performed every hour throughout the protocol along with exhaled breath collection

After SG surgery

It is a bariatric surgery where the stomach is reduced to about 15% of its original size, by surgical removal of a large portion of the stomach along the greater curvature.

Group Type EXPERIMENTAL

sleeve gastrectomy

Intervention Type PROCEDURE

liquid meal

Intervention Type OTHER

will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose

PET/scan

Intervention Type RADIATION

a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA

[7,7,8,8-2H]-palmitate

Intervention Type OTHER

i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.

indirect calorimetry

Intervention Type DEVICE

will be performed every hour throughout the protocol along with exhaled breath collection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

biliopancreatic diversion with duodenal switch

Intervention Type PROCEDURE

sleeve gastrectomy

Intervention Type PROCEDURE

liquid meal

will be consumed over 30 minutes with \[U-13C\]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose

Intervention Type OTHER

PET/scan

a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA

Intervention Type RADIATION

[7,7,8,8-2H]-palmitate

i.v. administration of \[7,7,8,8-2H\]-palmitate (in 25% human albumin) from time -60 to 360 min.

Intervention Type OTHER

indirect calorimetry

will be performed every hour throughout the protocol along with exhaled breath collection

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Four groups of 11 subjects each: obese subjects with T2D or with normal glucose tolerance undergoing either BPD-DS or SG for treatment of obesity. T2D and control subjects will be matched for age (± 3 years), BMI (± 2 kg/m2) and gender across both BPD-DS and SG.

Exclusion Criteria

* presence of overt cardiovascular disease, as assessed by history, physical exam, and abnormal EKG;
* treatment with a fibrate, a thiazolidinedione, a beta-blocker or other drugs known to affect lipid or carbohydrate metabolism (except statins, sulfonylurea, metformin, and other antihypertensive agents that can be temporarily stopped prior to the protocols);
* presence of liver or renal disease, uncontrolled thyroid disorder or other major illnesses;
* smoking (\>1 cigarette/day) and/or consumption of more than 2 alcoholic beverages per day;
* prior history or current fasting plasma cholesterol level \> 7 mmol/l or fasting TG \> 6 mmol/l;
* any other contraindication to temporarily stop current medications for hyperglycemia, lipids, or hypertension.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes